Although a prospective trial comparing clinical outcomes including OHSS to current triggers has yet to be conducted, a retrospective single center study compared rates of OHSS following hCG (n=40), GnRHa (n=99) or kisspeptin (n=122) in women at high risk of OHSS (defined as AFC or total number of follicles on day of trigger >23) (40). The gene discussed is KISS1; the disease is ovarian hyperstimulation syndrome.